Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Orexo's "Out the Monster" campaign wins a Gold Lions Health Award at the Cannes Lions Festival PR Newswire MORRISTOWN, N.J., June 25, 2015 MORRISTOWN, N.J., June 25, 2015 /PRNewswire/...
Orexo US launches new 8.6/2.1 mg ZUBSOLV® (buprenorphine/naloxone) sublingual tablet CIII: 8.6/2.1mg Offers additional option for physicians and patients to tailor maintenance treatment of opioid...
Orexo Features Positive Results from the ISTART Study at the 2014 AAAP Meeting Data presented from largest combination buprenorphine/naloxone opioid dependence trial ever conducted in the U.S. PR...
Orexo Launches ZUBSOLV Patient Assistance Program Helping eligible opioid dependent patients in need PR Newswire MORRISTOWN, N.J., Oct. 7, 2014 MORRISTOWN, N.J., Oct. 7, 2014 /PRNewswire/ -- As...
Orexo AB Begins Trading on OTCQX® PR Newswire NEW YORK, Nov. 13, 2013 NEW YORK, Nov. 13, 2013 /PRNewswire/ --OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected...
/C O R R E C T I O N -- Orexo U.S./ PR Newswire NEW YORK, Sept. 16, 2013 In the news release, Zubsolv® Now Available in the U.S. for the Maintenance Treatment of Opioid Dependence, issued...
Zubsolv® Now Available in the U.S. for the Maintenance Treatment of Opioid Dependence Zubsolv is a new, advanced formulation treatment option for opioid dependent patients that provides higher...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 1.185 | 1.185 | 1.185 | 400 | 1.185 | DR |
| 4 | 0.21 | 21.5384615385 | 0.975 | 1.185 | 0.975 | 233 | 1.09785714 | DR |
| 12 | -0.325 | -21.5231788079 | 1.51 | 1.55 | 0.889 | 306 | 1.14465455 | DR |
| 26 | -0.905 | -43.3014354067 | 2.09 | 2.35 | 0.889 | 654 | 1.83691069 | DR |
| 52 | -0.315 | -21 | 1.5 | 2.35 | 0.889 | 909 | 1.64300401 | DR |
| 156 | -2.825 | -70.4488778055 | 4.01 | 4.65 | 0.76 | 794 | 1.75830863 | DR |
| 260 | -5.415 | -82.0454545455 | 6.6 | 9 | 0.76 | 702 | 2.84446885 | DR |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
